Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance after autologous HSCT with Chidamide + BeMit in newly diagnosed peripheral T-cell lymphoma
ChiCTR2200060408Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 1 more, sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective remission rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR2200060408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060408.